Introduction

ConvaTec Group PLC is a specialist in medical products and technologies across advanced wound care, ostomy care, continence care and infusion care, categories that combine structural demographic growth with clinical complexity.

The Financial Times data dated 20 April 2026 shows ConvaTec (LSE:CTEC) at 237.40 pence, a 1.33% intraday decline and a 6.31% twelve-month decline. Against a FTSE 100 that has advanced 28.04%, that is a notable relative underperformance.

This article considers the company's positioning, the drivers of recent performance, and a balanced outlook.

Company overview

ConvaTec Group PLC develops, manufactures and markets medical products used in chronic and acute care. Its key franchises — advanced wound care, ostomy care, continence care and infusion care — serve both healthcare professionals and large numbers of patients managing long-term conditions.

The group's growth is underpinned by ageing populations, rising prevalence of chronic conditions, and continued innovation in product design. It invests in research and development, customer engagement, and geographic expansion as core long-term levers.

ConvaTec operates across North America, Europe and international markets, with varying reimbursement environments shaping commercial execution in each region.

Recent share price performance

A 6.31% twelve-month share-price decline is a moderate setback, reflecting both some disappointment on specific commercial metrics during the period and broader multiple compression across medtech names with more measured growth profiles.

The 1.33% intraday slip is in line with the sector's more cautious tone on soft market days.

Momentum over the last year

Momentum has been slightly negative, with the stock lagging a strongly rising index.

In medtech, low single-digit declines often reflect multiple recalibration rather than concerns about the underlying demand backdrop.

Sector and company-specific drivers

Key drivers include organic growth rates in each franchise, pricing dynamics, regulatory clearances for new products, and cost management including supply chain and input costs.

Geographic mix, with meaningful exposure to the US, also matters for reported results.

Investor sentiment

Sentiment towards ConvaTec is mixed: the underlying categories are considered attractive, but execution consistency is closely watched.

The modest intraday softness reflects that measured tone.

Risks and opportunities

Risks include slower-than-expected product launches, pricing pressure in specific markets, regulatory or reimbursement change, and FX effects.

Opportunities include continued demographic tailwinds, franchise innovation, disciplined cost management, and the potential for improved market sentiment as execution strengthens.

Wider industry and macro context

The medical products sector is supported by structural demographics and rising chronic disease prevalence, even as near-term pricing and reimbursement environments vary significantly between markets.

Supply chain and input cost behaviour remain important operational variables, as does the regulatory regime governing medical device approvals and labelling.

Within the FTSE 100, ConvaTec sits in a relatively small medtech cohort, which tends to trade on long-duration themes rather than short-term macro narratives.

Balanced outlook

A balanced outlook for ConvaTec combines favourable long-term structural drivers with the need for continued execution to re-engage investors.

The bull case is that innovation and disciplined growth across each franchise restore the stock's momentum. The cautious case is that competitive and reimbursement pressures delay that re-rating.

Conclusion

ConvaTec Group retains a meaningful role in chronic care segments, but the FT data from 20 April 2026 at 237.40p reflects a stock that is currently on the wrong side of the FTSE 100's strong one-year performance.

For LSE:CTEC investors, the path forward depends on consistent execution across franchises, disciplined cost management, and continued innovation that reinforces the long-term growth story.